Objective: In Alzheimer disease (AD), longitudinal changes of beta-amyloid1-42 (Aβ1-42),
tau, and phosphorylated tau at threonine 181 (ptau-181) in CSF have been reported in small …

Objective: CSF biomarkers amyloid beta 1-42 (Aβ42), total tau (tau), and tau phosphorylated
at threonine 181 (p-tau-181) are useful diagnostic markers for Alzheimer disease (AD). Less …

Objective: To determine the diagnostic value of CSF amyloid β (1–42)(Aβ42), CSF total tau,
and CSF tau phosphorylated at threonine-181 (Ptau-181) in early-onset Alzheimer disease …

Objective: To assess the relationship between Alzheimer disease (AD)–related pathologic
changes in frontal cortical brain biopsy and AD biomarkers in ventricular vs lumbar CSF, and …

Objective: To investigate the relationship between CSF biomarkers and cognitive profiles in
Alzheimer disease (AD). Methods: We included 177 patients with AD. Digit Span, Visual …

Background: Processes of Alzheimer disease (AD) likely begin years prior to the onset of
cognitive impairment (latent AD), progress though a prodromal phase of mild cognitive …

Background: CSF concentrations of tau and β-amyloid protein-42 (Aβ42) have been
extensively studied in AD. Few data are available concerning CSF levels of both proteins in …

Objective: To determine how amyloid β 42 (Aβ42), total tau (t-tau), and phosphorylated tau
(p-tau) levels in CSF behave in a large cohort of patients with different types of dementia …

OBJECTIVE: To compare CSF levels of beta-amyloid 1–42 (Aβ1–42), total tau (tau) and tau
phosphorylated at threonine 181 (ptau-181) between AD patients and controls according to …

Objective: To investigate if patterns of CSF biomarkers (T-tau, P-tau, and Aβ42) can predict
cognitive progression, outcome of cholinesterase inhibitor (ChEI) treatment, and mortality in …